全文获取类型
收费全文 | 25876篇 |
免费 | 1286篇 |
国内免费 | 136篇 |
学科分类
医药卫生 | 27298篇 |
出版年
2023年 | 114篇 |
2021年 | 511篇 |
2020年 | 271篇 |
2019年 | 331篇 |
2018年 | 460篇 |
2017年 | 354篇 |
2016年 | 446篇 |
2015年 | 447篇 |
2014年 | 609篇 |
2013年 | 771篇 |
2012年 | 1166篇 |
2011年 | 1246篇 |
2010年 | 716篇 |
2009年 | 616篇 |
2008年 | 1178篇 |
2007年 | 1251篇 |
2006年 | 1183篇 |
2005年 | 1130篇 |
2004年 | 1115篇 |
2003年 | 1098篇 |
2002年 | 1158篇 |
2001年 | 918篇 |
2000年 | 948篇 |
1999年 | 825篇 |
1998年 | 325篇 |
1997年 | 241篇 |
1996年 | 223篇 |
1995年 | 198篇 |
1994年 | 184篇 |
1993年 | 160篇 |
1992年 | 609篇 |
1991年 | 632篇 |
1990年 | 535篇 |
1989年 | 551篇 |
1988年 | 525篇 |
1987年 | 505篇 |
1986年 | 431篇 |
1985年 | 434篇 |
1984年 | 319篇 |
1983年 | 245篇 |
1979年 | 236篇 |
1978年 | 135篇 |
1977年 | 138篇 |
1974年 | 133篇 |
1973年 | 123篇 |
1972年 | 139篇 |
1971年 | 129篇 |
1970年 | 115篇 |
1969年 | 138篇 |
1967年 | 128篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
Naohiro Sekiguchi Shinya Rai Wataru Munakata Kenshi Suzuki Hiroshi Handa Hirohiko Shibayama Tomoyuki Endo Yasuhito Terui Noriko Iwaki Noriko Fukuhara Hiro Tatetsu Shinsuke Iida Takayuki Ishikawa Ryota Shiibashi Koji Izutsu 《Cancer science》2020,111(9):3327-3337
Tirabrutinib is a second‐generation Bruton’s tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment‐naïve (Cohort A) or with relapsed/refractory (Cohort B) Waldenström’s macroglobulinemia (WM). Patients were treated with tirabrutinib 480 mg once daily. The primary endpoint was major response rate (MRR; ≥ partial response). Secondary endpoints included overall response rate (ORR; ≥ minor response), time to major response (TTMR), progression‐free survival (PFS), overall survival (OS), and safety. In total, 27 patients (18 in Cohort A; 9 in Cohort B) were enrolled. The median age was 71 y, and the median serum immunoglobulin M level was 3600 mg/dL. Among the patients, 96.2% had the MYD88L265P mutation. MRR and ORR were 88.9% and 96.3%, respectively (Cohort A: MRR, 88.9%; ORR, 94.4%; Cohort B: MRR, 88.9%; ORR, 100%). Median TTMR was 1.87 mo. PFS and OS were not reached with a median follow‐up of 6.5 and 8.3 mo for Cohorts A and B, respectively. The most common adverse events (AEs) were rash (44.4%), neutropenia (25.9%), and leukopenia (22.2%), with most AEs classified as grade 1 or 2. Grade ≥ 3 AEs included neutropenia (11.1%), lymphopenia (11.1%), and leukopenia (7.4%). No grade 5 AEs were noted. All bleeding events were grade 1; none were associated with drug‐related atrial fibrillation or hypertension. Although the follow‐up duration was relatively short, the study met the primary endpoint. Therefore, tirabrutinib monotherapy is considered to be highly effective for both untreated and relapsed/refractory WM with a manageable safety profile. (JapicCTI‐173646). 相似文献
7.
8.
Koji Saito Takashi Saito Sumio Kawada 《Nihon Shokakibyo Gakkai zasshi》2006,103(10):1176, 1179-1176, 1180
9.
Masahiro Yamauchi Hiroko Kusano Etsuko Saito Takeshi Iwata Masashi Nakakura Yasuki Kato Takaaki Uochi Shiro Akinaga Noboru Aoki 《Journal of controlled release》2006,114(2):268-275
Previously, we demonstrated that wrapping dextran fluorescein anionic/cationic lipid complexes with neutral lipids produced a stable formulation that markedly increased the duration of the compound in plasma after intravenous administration to rats. The improved drug-delivery properties of the wrapped liposomes (WL) relative to other formulations suggested that this technology could offer important advantages for the administration of other polyanionic drugs, including antisense oligodeoxynucleotides (ODN). In the present study, we investigated the value of WL for formulating fluorescence-labeled phosphorothioated ODN (F-ODN). WL encapsulating F-ODN/cationic lipid complexes were prepared efficiently using similar methodology to that used in our earlier study. Studies confirmed that these WL were stable in vitro. Following intravenous administration to mice, free F-ODN and naked F-ODN/cationic lipid complexes were rapidly eliminated whereas administration of the WL resulted in high blood concentrations of drug that were maintained for several hours. Additional studies were conducted in mice that were inoculated with tumor cells (Caki-1 xenograft model, human kidney); in these experiments, intravenous administration of WL delivered 13 times more F-ODN to the tumor site than achieved after injection of free F-ODN. 相似文献